Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Condensed Consolidated Statements of Operations and Comprehensive Loss    
Revenues $ 211 $ 410
Cost of goods sold 40 107
Gross profit 171 303
Operating expenses:    
Research and development 2,511 1,862
General and administrative (related party of $189 and $393) 6,634 5,365
Total operating expenses 9,145 7,227
Operating loss (8,974) (6,924)
Other income (expense):    
Interest expense (related party of $608 and $614) (609) (614)
Interest income 36 4
Forgiveness of note payable and accrued interest - SBA loan 607 0
Total other income (expense) 34 (610)
Consolidated net loss (8,940) (7,534)
Net loss attributable to noncontrolling interest 1 1
Net loss attributable to iBio, Inc. (8,939) (7,533)
Preferred stock dividends (66) (66)
Net loss attributable to iBio, Inc. stockholders (9,005) (7,599)
Comprehensive loss:    
Consolidated net loss (8,940) (7,534)
Other comprehensive loss - unrealized loss on debt securities (1) (7)
Other comprehensive loss - foreign currency translation adjustments 0 0
Comprehensive loss $ (8,941) $ (7,541)
Loss per common share attributable to iBio, Inc. stockholders - basic $ (0.04) $ (0.05)
Weighted-average common shares outstanding - basic and diluted 217,876 162,442